Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Morin

Clinical Cardiac Electrophysiology San Francisco, CA Medical Doctor

NPI 1306011044 CMS profile 570252

500 Parnassus Ave Rm Mue 432, San Francisco, CA 94143

Open in the dashboard

General payments

$265,323

458 records reported · program years 2019–2025

Research payments

$2,562

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,948 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Daniel Morin of San Francisco, CA is reported in the CMS Open Payments database as having received $265,323 across 458 general payments and $2,562 in research payments paid to them. Separately, studies naming them as principal investigator received $16,948 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47,476 85
2024 General $32,687 80
2024 Research $1,446 1
2023 General $42,856 59
2023 Research $1,117 1
2022 General $49,864 94
2021 General $24,197 38
2020 General $31,975 38
2019 General $36,269 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Morin
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Daniel Morin were reported at $47,476. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Daniel Morin Clinical Cardiac Electrophysiology median Middle half National median
2019 $36,269 $2,361 $585–$8,260 $163
2020 $31,975 $993 $247–$4,351 $114
2021 $24,197 $1,185 $326–$4,739 $132
2022 $49,864 $2,073 $554–$6,789 $149
2023 $42,856 $2,568 $759–$8,159 $160
2024 $32,687 $2,557 $703–$7,403 $164
2025 $47,476 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $148,354 128 payments
  2. Abbott Laboratories $56,595 107 payments
  3. Boston Scientific Corporation $22,743 59 payments
  4. ZOLL Medical Corporation $13,797 5 payments
  5. Medtronic, Inc. $11,077 39 payments
  6. AltaThera Pharmaceuticals LLC $3,199 4 payments
  7. Cook Incorporated $2,400 1 payment
  8. Ebr Systems, Inc. $2,193 14 payments
  9. Biosense Webster, Inc. $1,051 15 payments
  10. Janssen Pharmaceuticals, Inc $510 25 payments
  11. Other $3,405 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $159,773 68 payments
  2. Consulting Fee $52,802 37 payments
  3. Food and Beverage $20,335 289 payments
  4. Travel and Lodging $18,151 56 payments
  5. Honoraria $9,500 3 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $4,600 3 payments
  7. Grant $147 1 payment
  8. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. LifeVest $148,354 128 payments
  2. Defibrillator $13,797 5 payments
  3. FLEXABILITY $12,650 6 payments
  4. FlexAbility Ablation Catheter Cardiac Arrhythmias and Heart Failure $12,124 17 payments
  5. ENSITE $9,688 14 payments
  6. TACTICATH ABLATION CATHETER, SENSOR ENABLED $7,737 7 payments
  7. MERLIN@HOME $6,265 19 payments
  8. FlexAbility Ablation Catheter Electrophysiology $5,196 1 payment
  9. General - Therapies $5,000 2 payments
  10. Sotalol Hydrochloride $3,199 4 payments
  11. Other $19,714 229 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,562 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,761

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,157,608

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

53.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 546 $581,383
Xarelto Rivaroxaban Brand 463 $454,599
Multaq Dronedarone Hcl Brand 40 $46,299
Verapamil Sr Verapamil Hcl Brand 161 $21,690
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 42 $13,837
Flecainide Acetate Generic 220 $10,057
Verapamil Er Verapamil Hcl Brand 141 $7,708
Metoprolol Succinate Generic 448 $6,083
Propafenone Hcl Er Propafenone Hcl Brand 21 $4,959
Amiodarone Hcl Generic 199 $3,351

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$65,504

Medicare's payments for the services billed

Medicare patients

446

Average age 76

Services billed

1,275

192 women, 254 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 67%
Heart failure 50%
Arthritis 47%
Ischemic heart disease 44%
Chronic kidney disease 41%
Diabetes 37%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $2,099
$2,099 14 —
XARELTO
  • Janssen Pharmaceuticals, Inc $136
$136 463 —
Repatha
  • Amgen Inc. $62
$62 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $60
$60 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

460 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record